๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Immunocompetence and malignant lymphoma: Immunologic status before therapy

โœ Scribed by Thomas C. Anderson; Stephen E. Jones; Barbara J. Soehnlen; Thomas E. Moon; Kathy Griffith; Patricia Stanley

Publisher
John Wiley and Sons
Year
1981
Tongue
English
Weight
785 KB
Volume
48
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Monitoring of immunologic status of pati
Monitoring of immunologic status of patients receiving BCG therapy for malignant disease
โœ Nicholas J. Gross; A. C. Eddie-Quartey ๐Ÿ“‚ Article ๐Ÿ“… 1976 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 866 KB

BCG immunotherapy in a standard regime was administered by scarification to 26 selected patients with controlled malignant disease, 14 with lung cancer and 12 with melanoma. All were followed for 12 months after the first BCG administration or until death. During the first 3 months, when BCC was giv

Immunologic aspects and pathology of the
Immunologic aspects and pathology of the malignant lymphomas
โœ Costan W. Berard; Elaine S. Jaffe; Raul C. Braylan; Risa B. Mann; Koji Nanba ๐Ÿ“‚ Article ๐Ÿ“… 1978 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 933 KB

Malignant lymphomas have traditionally been classified on solely morphologic grounds. With new immunologic and cytochemical techniques, it has been possible to characterize normal cells of the T-lymphocytic, B-lymphocytic, and monocyte-macrophage systems. Application of these methodologies to malign

Combined cyclophosphamide, vincristine,
Combined cyclophosphamide, vincristine, and prednisone therapy of malignant lymphoma
โœ James K. Luce; Jess F. Gamble; Henry E. Wilson; Raymond W. Monto; Bertha L. Isaa ๐Ÿ“‚ Article ๐Ÿ“… 1971 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 914 KB

A combination of intravenous cyclophosphamide and vincristine (Oncovin) and oral prednisone (COP) was given every 2 weeks to 262 patients with disseminated Hodgkin's disease, lymphosarcoma, reticulum cell sarcoma, a n d follicular lymphoma. A complete remission was produced in 36% of patients with H